Barclays’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-49,170
| Closed | -$1.95M | – | 5415 |
|
|
2024
Q1 | $1.95M | Sell |
49,170
-31,127
| -39% | -$918K | ﹤0.01% | 2592 |
|
|
2023
Q4 | $1.53M | Buy |
80,297
+71,171
| +780% | +$989K | ﹤0.01% | 3125 |
|
|
2023
Q3 | $104K | Buy |
9,126
+2,801
| +44% | +$34.5K | ﹤0.01% | 3587 |
|
|
2023
Q2 | $65K | Sell |
6,325
-5,754
| -48% | -$51.9K | ﹤0.01% | 3725 |
|
|
2023
Q1 | $93.3K | Buy |
12,079
+5,999
| +99% | +$47.8K | ﹤0.01% | 4224 |
|
|
2022
Q4 | $44.7K | Buy |
6,080
+5,418
| +818% | +$34.6K | ﹤0.01% | 4587 |
|
|
2022
Q3 | $5K | Sell |
662
-121
| -15% | -$997 | ﹤0.01% | 4516 |
|
|
2022
Q2 | $7K | Sell |
783
-1,103
| -58% | -$9.51K | ﹤0.01% | 4730 |
|
|
2022
Q1 | $17K | Sell |
1,886
-12,212
| -87% | -$106K | ﹤0.01% | 4491 |
|
|
2021
Q4 | $196K | Buy |
14,098
+9,351
| +197% | +$116K | ﹤0.01% | 3575 |
|
|
2021
Q3 | $51K | Buy |
4,747
+3,278
| +223% | +$30.2K | ﹤0.01% | 4107 |
|
|
2021
Q2 | $13K | Sell |
1,469
-12,636
| -90% | -$137K | ﹤0.01% | 4584 |
|
|
2021
Q1 | $150K | Buy |
+14,105
| New | +$176K | ﹤0.01% | 3832 |
|
|
2020
Q4 | – | Sell |
-2,793
| Closed | -$25K | – | 5211 |
|
|
2020
Q3 | $25K | Buy |
+2,793
| New | +$25.5K | ﹤0.01% | 4857 |
|
|
2019
Q4 | – | Sell |
-2
| Closed | – | – | 6925 |
|
|
2019
Q3 | $0 | Buy |
+2
| New | +$9 | ﹤0.01% | 7234 |
|
|
2018
Q2 | – | Sell |
-134
| Closed | -$1K | – | 7368 |
|
|
2018
Q1 | $1K | Buy |
+134
| New | +$1.32K | ﹤0.01% | 6981 |
|
|
2017
Q3 | – | Sell |
-675
| Closed | -$6K | – | 7100 |
|
|
2017
Q2 | $6K | Buy |
+675
| New | +$6.47K | ﹤0.01% | 6202 |
|
|
2017
Q1 | – | Sell |
-1,000
| Closed | -$9K | – | 7042 |
|
|
2016
Q4 | $9K | Hold |
1,000
| – | – | ﹤0.01% | 5953 |
|
|
2016
Q3 | $33K | Sell |
1,000
-24
| -2% | -$584 | ﹤0.01% | 5225 |
|
|
2016
Q2 | $18K | Buy |
1,024
+24
| +2% | +$426 | ﹤0.01% | 5322 |
|
|
2016
Q1 | $16K | Hold |
1,000
| – | – | ﹤0.01% | 5316 |
|
|
2015
Q4 | $28K | Hold |
1,000
| – | – | ﹤0.01% | 5085 |
|
|
2015
Q3 | $48K | Buy |
+1,000
| New | +$65.7K | ﹤0.01% | 5031 |
|
Barclays's ALPN Position: Q2 2024 in Review
Barclays sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 49,170 shares — an estimated $1.95M sold.
Barclays first reported a position in ALPN in Q3 2015 and held it in 23 quarters. The position peaked at $1.95M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Barclays reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Barclays sold 49,170 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $1.95M.
- Barclays first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 23 quarters.
- Barclays's Alpine Immune Sciences Inc position peaked at $1.95M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.